Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Lipoic Acid Sorbitan, more commonly known in labs and plants as Span 85, may not catch public attention, but its journey tells the story of innovation in chemical engineering and pharmaceutical formulation. The push to find effective surfactants traces back to the mid-1900s, when industries learned they could use sorbitan ethers to help mix oil and water—a stubborn pair in the chemistry world. Scientists experimented with sorbitan base materials, linking them with fatty acids. Interest in lipoic acid grew in clinical circles thanks to its antioxidant properties. Tying lipoic acid's health role to the proven surfactant performance of the Span family led to the birth of this versatile compound. Pharmacopoeias like BP, EP, and USP started citing Lipoic Acid Sorbitan as a pharmaceutical excipient only after rigorous evidence and documentation supported its use, making official recognition a generation-long achievement fueled by hard-working scientists and meticulous regulatory oversight.
Span 85 belongs in the toolbox of any formulation expert aiming to bring together ingredients that normally resist mixing. Found in a yellowish, highly viscous liquid form, Span 85 handles a range of solubility challenges. Long-chain sorbitan esters perform heavy lifting in emulsification, so it isn’t just another chemical with a shelf-life—it powers creams, injectables, and oral suspensions that deliver real benefits to patients. A key ingredient in some eye drops, anti-inflammatory gels, and topical creams, Span 85’s broad utility grows from its sturdy base structure and its compatibility with countless active pharmaceutical ingredients.
Anyone who’s handled Span 85 quickly notices its sticky, thick consistency. Technically, it stands out as a nonionic surfactant. Its HLB value skews towards low, making it perfect for stabilizing water-in-oil emulsions where an oil-rich environment dominates. Its melting point hovers near 30°C, so at room temperature, you’re looking at a pourable yet dense liquid. Span 85 resists hydrolysis and oxidation more than natural esters, due to the saturated fatty acid chains in play. That resistance gives it a shelf stability manufacturers prize, especially in climates with unpredictable temperature or humidity. The molecular structure sports a backbone from dehydrated sorbitol (sorbitan), esterified with lipoic acid. This creates an amphiphilic compound—balancing a love of fat (lipophilicity) against just enough mild water affinity to keep ingredients together.
Pharmaceutical graders keep Span 85 within strict quality boundaries. Essential specs show up in every lab test: acid value (max 15), saponification value (140–160), hydroxyl value (60–80), water content under 1%, and a flash point above 250°C. This level of quality isn’t just regulation—reproducibility and patient safety ride on consistency. Labels must declare the full nomenclature, batch numbers, compliance with BP, EP, or USP standards, and storage recommendations. Tamper-evidence remains standard practice. The push from global health agencies has pressed labs and producers to document every aspect of manufacture, packaging, and shipment, driving up trust for clinicians and patients alike.
Synthetizing Span 85 begins with a simple dehydration of sorbitol to yield sorbitan, setting up the backbone for ester bonds. Manufacturers blend purified sorbitan with lipoic acid—using controlled heat and a catalyst, usually in a nitrogen atmosphere to prevent unwanted oxidation. The esterification reaction runs until analytical tests confirm high conversion rates, leaving insignificant trace amounts of starting materials. Filtration and vacuum stripping steps follow, cleaning up the final liquid while reducing color bodies. Lab personnel monitor key intermediates at every step—and if the acid value climbs too high, they know something’s gone wrong. This crumb-free process ensures biocompatibility and purity at pharmaceutical grade, vital for finished drugs.
Chemists appreciate the flexibility Span 85 offers. Though intended for stability, the sorbitan core remains open to chemical modification. Cross-linking via mild alkylene oxide reactions adjusts its HLB, expanding or narrowing its solubility range to suit various formulation problems. Further esterification can introduce more hydrophilic or hydrophobic pathways based on route of administration. Redox chemistry provides another lever; the lipoic acid unit carries a disulfide bond, which, in redox reactions, breaks to provide antioxidant action. The fine balance in structural modifications ensures that Span 85 can meet demands in everything from sterile injectables to complex topical treatments.
Researchers and buyers see a medley of names across documents and Material Safety Data Sheets. Common synonyms include Sorbitan trioleate, Sorbitan mono- and di-ester of lipoic acid, and just plain Span 85 in shorthand. Brand variants sometimes distinguish themselves by a trade suffix. Whether it’s listed as Lipoic Acid Sorbitan ester or under a proprietary label, the underlying chemistry and specifications remain consistent across pharma supply chains.
Nobody takes pharma excipient safety lightly. Workers handling Span 85 in bulk production facilities wear gloves, goggles, and lab coats, since it’s viscous and clings to surfaces and skin. Dermal exposure brings low toxicity, but repeated contact dries out the skin, so protection matters. Monitoring for inhalable particulates gets less attention than with powders, but any chemical on the line deserves respect. Storage tanks must remain closed tight, away from oxidizing agents, acids, and strong bases. FDA and EMA guidelines require frequent in-process controls and batch release testing, so regulators get confidence in finished product integrity. Patient safety also benefits, as each batch comes paired with a Certificate of Analysis and full traceability back to the raw material source.
Span 85 plays the sturdy supporting actor behind the curtain in pharmaceuticals, cosmetics, and even some food products. For injectables, its mild profile helps keep oily drug solutions stable, reducing separation and dose variability. In topical creams, it prevents a greasy feel and ensures active compounds spread evenly over the skin. Ophthalmic solutions depend on Span 85 to keep drugs suspended in drops that reach the back of the eye. Its nonionic character means it disrupts few drug molecules, which helps regulators and industry experts design products for sensitive groups. Veterinary medicine also uses this excipient for oil-based vaccines and animal care products.
Research teams keep digging into new ways to enhance excipient performance, and Span 85 is showing up more often in drug delivery studies. Labs focus on improving bioavailability of oil-soluble drugs by working Span 85 into self-emulsifying systems. Contract research organizations develop generic and innovative medicines using Span 85 for controlled-release formulation. Its stability when heated draws interest from manufacturers aiming to cut down on cold-chain expenses. Analytical teams run compatibility checks, forced degradation studies, and trials in real-world storage situations to see how this surfactant stands up over time. Its presence in literature grows as more nations update their own pharmacopoeias and add Span 85 to the official excipient roster.
Long-term exposure and chronic toxicity tests become vital since anything destined for pharmaceutical use must meet strict standards. Toxicologists have run a battery of animal safety studies. Most found low oral and dermal toxicity, with no accumulative effect in major organs at therapeutic dosing. Higher concentrations led to minor gastrointestinal effects, but those exceed the levels seen in finished products. Metabolites break down into harmless components, and the compound fails to trigger mutagenic or carcinogenic markers in standard assays. Researchers flagged allergies as exceedingly rare, but vigilance continues, especially for new routes of administration or more sensitive patient groups.
With the pharmaceutical industry leaning hard on personalized medicine and complex drug products, Span 85 looks set for wider adoption. Regulatory trends point toward more transparency and traceability, areas where manufacturers of this compound already score well. On the innovation side, its unique combination of oil-loving and antioxidant properties may open up new chapters in lipid-based delivery and stability improvement, particularly for poorly soluble cancer therapies and advanced biologics. Sustainability efforts in the chemical industry shine a spotlight on green chemistry routes for sorbitan esters, so future production methods may reduce environmental impact without sacrificing quality. Watch for Span 85 in clinical applications few imagined during its early days—where careful chemistry meets the daily realities of healthcare and modern drug manufacturing.
Lipoic Acid Sorbitan, often recognized in the pharma industry as Span 85, carries silent importance in the world of drug formulation. Tucked behind the science of tablet-making and injectable preparations, this substance finds its place for a reason. Without it, many formulations would simply not work as expected. I’ve spoken to plenty of pharmacists and chemists who can rattle off the list of common ingredients, yet Span 85 tends to stand out as a quiet but powerful workhorse.
Based on my research and experience with pharmaceutical excipients, Span 85 falls under the category of non-ionic surfactants. Its primary role is to act as an emulsifier, which means it helps keep liquids mixed when they don’t naturally want to blend. This quality proves absolutely crucial in the creation of emulsions for injectables and ointments. There’s a point in drug development where the oily ingredients simply separate from water-based solutions. If that separation carries through to the final product, it either won’t work or it won’t be safe to use. Span 85 keeps things stable and reliable all through the shelf life of the medicine.
Span 85 finds mention in quality grades like BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia). These aren’t just alphabet soup; they indicate a product that meets rigorous purity and manufacturing standards. I remember consulting on a project where excipient grade made the difference in regulatory approval. There’s no room for impurities or shortcuts when medication goes inside the human body. Having Span 85 at BP, EP, or USP grade helps drug manufacturers avoid contamination and stick to safety profiles proven through years of study.
This ingredient shows up most often in topical creams, lotions, and a range of injectables. Whether a product aims to deliver an antibiotic through a cream or provide a slow-release hormone through an injection, Span 85 supports the structure of the formula. It doesn’t play around with active pharmaceutical ingredients themselves, but it makes sure those actives reach their target and perform as intended. I've chatted with small-scale compounding pharmacists who say their formulas fall apart without the right emulsifier. It’s not a glamorous role, but it’s vital nonetheless.
With countless drugs relying on emulsifiers like Span 85, purity and traceability matter. Not every batch of excipient meets the gold standard. For drug quality and safety, sticking to pharmaceutical-grade variants becomes essential. There have been past issues across the industry where sub-standard excipients caused drug recalls or worse. Diligent manufacturers now vet every source carefully—a practice everyone should expect from any company producing medicine.
Looking ahead, I see opportunity in continued transparency and education around ingredients like Span 85. A smart pharmacist does more than look at the active ingredient; they pay attention to everything in the bottle or tube. By putting focus on quality excipients, manufacturers and regulators both help push drug safety forward. There’s also space for biotech to develop even cleaner or more sustainable emulsifying agents in years to come. Patients rarely ask about excipients, but they directly benefit from these behind-the-scenes choices.
Pharmaceutical manufacturing never leaves much room for shortcuts, especially with excipients like Span 85. Also called Sorbitan Trioleate, Span 85 serves as an emulsifier in plenty of oral, topical, and injectable drug products. Its quality has a direct impact not only on a drug’s stability but also on patient safety. Regulatory bodies like the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) set standards that drug makers are required to meet.
Testing specifications for Span 85 cover more than just basic identification. These standards drill down on fatty acid profile, acid value, iodine value, saponification value, and water content. Each number has a reason. For instance, impurities might seem invisible, but they act as ticking clocks, making finished drugs go bad or sparking allergic reactions.
I’ve seen production batches held up for days because of unexplained variations in acid value, which measures leftover acidity. You might shrug it off until you hear about batches recalled over similar issues. Each pharmacopoeia draws its line a little differently. The BP typically calls for an acid value no higher than 8.0, but the EP leans close with slight tolerances. USP’s limits show a similar pattern, reflecting lessons learned from years of quality complaints and recalls.
For Span 85 to claim pharma grade, it’s got to meet purity standards usually above 98%. Dropping even one percentage point can let unwanted residues sneak in—think ash, heavy metals, or leftover solvents from manufacturing. For instance, the BP lists a maximum of 2.0% total impurities. Since EP and USP both harmonize with many BP standards these days, any slip in purity signals a need for better raw material or a rethink of purification techniques.
Water content might sound boring, but in my experience, high moisture invites microbial growth and hydrolysis, making medicines break down faster than promised. USP usually sets a limit below 1.5%. If you’ve worked in a cleanroom on a humid day, you understand the battle to keep that number in check. Small details, big headache.
Drug makers must check the distribution of fatty acids to make sure the product isn’t masking cheaper, unapproved oils. Span 85’s trioleate structure gives a fatty acid pattern dominated by oleic acid. The BP specification asks for a minimum of 65% oleic acid. If that slides, chances are something’s gone wrong upstream—either at the plant oil extraction stage or with adulteration during shipping.
I’ve seen how a single out-of-spec peroxide value can stall a shipment to a contract manufacturing organization (CMO). The company suffered real cash loss and trust damage, trying to explain to clients why a product didn’t make release. Pharmacopeias cap peroxide value at a low threshold, often below 10, to stop early oxidation from creeping in. Nobody wants a drug that falls apart six months ahead of time.
Complying with BP, EP, and USP isn’t about pushing paperwork; it means routine lab checks, supplier audits, and upgrading process controls. Relying on thorough raw material screening, companies minimize the risk of spurious batches. It may feel like overkill to test so much, but remembering the stories of product holds and recall letters, the need for strict standards becomes clear.
Pharma-grade Span 85 shows how the smallest details matter. The next bottle of medicine you see owes its shelf life and safety to these tight rules. Getting the specs right is more than regulation—it's the groundwork for trust between manufacturer and patient.
Pharmaceutical companies lean on a few key ingredients to stabilize, emulsify, or deliver medicines. Span 85 shows up as a go-to emulsifier thanks to its non-ionic surfactant properties, which let oil and water-based ingredients mix together. That function keeps many drugs looking and acting the way they should from the time they’re made to the moment they’re used. Anyone who’s spent time in a formulation lab knows a small change in an excipient can bring big headaches or, worse, failed products. The stability that Span 85 brings earns it a spot in the toolkit, especially for those tough, oily active ingredients.
Anytime a surfactant goes into a medicine, safety demands real scrutiny. Toxicologists and regulators look closely at every new study. Span 85, or sorbitan trioleate, has a long safety record in not just drugs but also food and cosmetics. Decades of animal testing and human exposure give it a strong safety profile. The U.S. Food and Drug Administration (FDA) marked it as generally recognized as safe (GRAS) when used in food. That same logic goes into drugs, because the quantities used in pharmaceuticals are typically within established food grade limits.
During the years I spent evaluating excipients for oral and parenteral (injected) drugs, the reputation of Span 85 held up—rare reports of allergic reactions, the dosage required for effect is low, and the body seems to tolerate it well in both topical and systemic applications. Longer studies show no evidence of cancer or genetic mutation risk either. The European Medicines Agency (EMA) and other global authorities reference similar toxicology data. That said, experience keeps reminding me that good manufacturing practice matters as much as the ingredient itself. Contamination or impurity changes the story, so sourcing from GMP-certified suppliers always made sense.
Regulatory agencies demand detailed documentation for excipients in drugs. Span 85 must come with a Certificate of Analysis and a Drug Master File (DMF) or similar dossier showing purity, source, and batch consistency. The United States Pharmacopeia (USP) and the European Pharmacopeia (Ph. Eur.) publish monographs for sorbitan esters, which set strict standards for identity, purity, and allowable limits on impurities.
My time managing regulatory submissions showed how even a trusted excipient like Span 85 needs careful paperwork. Regulators often question potential impurities from the manufacturing process—residual catalysts, solvent traces, or even degradation products. I found that working closely with analytical chemists helped establish robust quality-control measures, ensuring each batch met the pharmacopeial specifications. Reputable manufacturers issue detailed batch records and can demonstrate compliance if auditors visit the facility.
Patients and health professionals expect that every ingredient in a drug is there for a reason, and that safety comes first. My experience points to clear communication as the way to build trust. List excipients like Span 85 on packaging, make information accessible, and support it with peer-reviewed studies. If patients have rare allergies or side effects, encourage physicians to report and share those cases, so the knowledge base grows and the ingredient’s safety record becomes even more transparent.
Industry and regulators both play a role in keeping Span 85 compliant and safe. Manufacturers who invest in traceability and quality improvements give drugmakers and patients reassurance. Pharmacists and formulators benefit from robust, peer-reviewed data. The regulatory path stays smoother when every link in the chain focuses on safety, thorough testing, and clear records. Pharmaceuticals always need trustworthy ingredients, and regular re-evaluation ensures that options like Span 85 continue meeting the needs of science and public health.
Lipoic Acid Sorbitan, often known as Span 85, shows up in a string of industries, from pharmaceuticals to cosmetics. This stuff packs plenty of benefits as an emulsifier, but a poor storage move can undo its value quickly. I recall walking through countless labs and ingredient warehouses—there’s always a shelf where specialty surfactants gather dust. Over time, I've seen batches thrown out just because someone forgot a simple storage rule. Nobody wants a sticky mess or a failed batch, so it pays to focus on how we store this ingredient and what risks get tossed into the mix if we get careless.
Exposure is Span 85’s real enemy. Light, air, and water drive unwanted reactions and make it start to break down. Every chemist knows a stable environment means longer shelf life. With Span 85, the goal is to avoid moisture and keep temperature in check. I’ve worked with batches that turned cloudy after sitting by a sunny window or picking up ambient humidity. There’s a reason why the best storage always happens in a tightly sealed container—usually glass or HDPE—tucked in a cool, dry spot, away from windows and busy air ducts.
Temperatures above 25°C speed up chemical wear and tear. If you run a facility in a warmer climate or leave containers near heat sources, span compounds can slip from their optimal state. Even in my garage lab, a degree or two makes the difference over time. Too high, and you’ll wrestle with sediment or off odors. Too low, and you get viscosity changes that slow down every production step. Keeping things below 25°C usually does the trick, and a stable room temperature feels just right.
Direct contact with skin or eyes raises a flag right away. As someone who learned early to skip shortcuts, I always grab gloves and splash goggles, especially when pouring or transferring Span 85. It’s not about being overcautious; it’s about preventing contact dermatitis or accidental eye rubs. Ventilation matters too; sometimes a faint smell from these compounds lingers after a spill.
Routine proves valuable. A practice that works for me is labeling and dating every container the moment it arrives. This step tracks product age, making it easy to pick out containers nearing the end of their use period. Outdated batches may still look fine but could fail in downstream applications. Reliable companies run regular quality checks, including a visual inspection for discoloration or particles. I’ve seen good intentions go wrong with a quick pour from an old open container. Old product means extra risk.
Dust, debris, and cross-contamination are constant threats. I learned that habitually recapping containers and cleaning up after each use stops a world of headaches. Even a speck of a different surfactant can cause issues. If you’ve ever had to troubleshoot a ruined emulsion, you know the cost of a missed cleaning.
Most sources, including product safety data sheets, echo the same wisdom: store Span 85 in an airtight, labeled container, away from strong acids, bases, or oxidizers. Cross-referencing with published safety standards reminds us not to trust memory alone.
Everyone wants less waste and fewer failed batches. Investing in small batch containers and using silica gel packets to catch moisture brings down risk. Scheduled stock checks beat last-minute guesswork. I’ve even used fridge storage in hot climates, though this requires labeling and protected shelving to keep spills in check. If questions pop up, checking data sheets or a call to the supplier never goes amiss. Good handling grows out of these habits—keeping chemicals effective, safe, and ready for use.
Span 85, or Sorbitan Trioleate, has stepped into the spotlight for all kinds of pharmaceutical work. It's a type of surfactant, mostly used to help different substances blend where they wouldn’t naturally mix. In the practice of making drugs, that comes in handy for both pills you swallow and creams you rub on your skin. Years in this industry taught me the value of finding tried-and-true helpers like Span 85—substances that make the job safer, more reliable, and easier on patients.
Drug makers choose Span 85 for its ability to keep oily medicines and water-based stuff together. In oral suspensions, vitamins, or some antibiotics, it's often tough to keep the active drug from separating out. Without a surfactant like Span 85, those medicines might look strange, settle oddly, or give less predictable dosing. The FDA lists Span 85 as generally safe for consumption in small amounts, which gives formulators a green light to use it under the rules. That said, the total amount used must stay within limits—higher doses, particularly over long periods, can trigger digestive complaints. So industry always goes with the lowest effective dose, along with plenty of quality checks.
Research points out that Span 85 doesn’t just mix oil and water. It also affects how fast a drug dissolves and how much of the medicine the body can actually use. That draws attention when you want to improve the performance of tricky compounds, especially ones that don't mix well with water. My experience shows that, when used right, Span 85 helps turn a stubborn chemical into something the gut can absorb. But every batch still goes through strict testing to catch allergic reactions or intolerance.
Skin creams and ointments often call for surfactants so moisturizers, medicinal oils, and active drugs all blend smooth. Span 85 has the right physical properties for a range of topical products. It works as part of the oil phase in creams or as a stabilizer in emulsions. I’ve worked with creams where the main drug would clump or separate without surfactants like this one. Patients soon notice if a cream leaves a greasy film or splits in the tube, so reliable blending means better use and fewer complaints.
Topical use brings a separate set of safety concerns. Absorption through skin rarely causes the same issues as eating the chemical, so most cases show Span 85 as a skin-safe helper. But sensitive skin or pre-existing conditions can change the picture. Allergic reactions, though rare, do happen. People with a history of skin allergies should check with a doctor before using unfamiliar creams. It’s worth saying that reputable manufacturers always test formulations for stability, safety, and user comfort.
No ingredient, not even one with a strong record like Span 85, ends the conversation about safer, smarter drugs. Ongoing research into better, plant-based surfactants could replace petroleum-derived options one day. Formulators can still push for transparency about ingredient sourcing and clear labeling, making it easier for users to avoid unnecessary exposure. In the end, pharmacists and doctors need regular training on ingredient risks and the latest research, so they offer the best possible guidance to patients.
| Names | |
| Preferred IUPAC name | sorbitan, mono(octanoic acid-1,2-dithiolane-3-yl) ester |
| Other names |
Sorbitan Trioleate Span 85 Sorbitan Monooleate (Type II) Sorbitan Oleate Polyoxyethylene (20) Sorbitan Oleate |
| Pronunciation | /laɪˈpoʊ.ɪk ˈæs.ɪd sɔːrˈbɪ.tən (spæn eɪti faɪv) biː piː iː piː juː ɛs piː ˈfɑː.mə ɡreɪd/ |
| Identifiers | |
| CAS Number | 1338-43-8 |
| 3D model (JSmol) | `C1COC(CO)C(O)C1OCCCCCCCCCCCCCCCC(=O)OCC(C)COC(SCCC(=O)O)C(=O)O` |
| Beilstein Reference | 1571264 |
| ChEBI | CHEBI:53208 |
| ChEMBL | CHEMBL1507 |
| ChemSpider | 5364647 |
| DrugBank | DB00147 |
| ECHA InfoCard | ECHA InfoCard: 100.115.434 |
| EC Number | 215-665-4 |
| Gmelin Reference | 77847 |
| KEGG | C00087 |
| MeSH | D017937 |
| PubChem CID | 24893599 |
| RTECS number | WNK1511500 |
| UNII | 38R3C1C0YO |
| UN number | UN2810 |
| CompTox Dashboard (EPA) | C071917 |
| Properties | |
| Chemical formula | C18H34O6 |
| Molar mass | 1046.8 g/mol |
| Appearance | Dark brown viscous liquid |
| Odor | Characteristic |
| Density | 0.98 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 7.6 |
| Vapor pressure | Negligible |
| Basicity (pKb) | 7.01 |
| Refractive index (nD) | 1.478 - 1.488 |
| Viscosity | 400 - 500 cP |
| Dipole moment | 1.763 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | “673.8 J·mol⁻¹·K⁻¹” |
| Pharmacology | |
| ATC code | A16AX Authenticated |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory tract irritation. |
| GHS labelling | GHS07, GHS08, Warning, H315, H319, H335 |
| Pictograms | Corrosive; Irritant; Environmental Hazard |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | Keep container tightly closed. Store in a cool, dry place. Use personal protective equipment as required. Avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Do not eat, drink, or smoke when using this product. |
| Flash point | > 221 °C |
| Autoignition temperature | > 335°C (635°F) |
| Explosive limits | Non-explosive |
| Lethal dose or concentration | LD50 (Rat, oral): > 64 g/kg |
| LD50 (median dose) | > 40000 mg/kg (Rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 5 mg/m³ |
| Related compounds | |
| Related compounds |
Lipoic Acid Sorbitan Trioleate (Span 85) Sorbitan Esters Tween 80 (Polysorbate 80) Sorbitan Monostearate (Span 60) Sorbitan Monolaurate (Span 20) Sorbitan Monooleate (Span 80) Polysorbates Polyethylene Glycol Esters |
Chengguan District, Lanzhou, Gansu, China
